Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.
Chairman / CEO at Advaxis
CFO, Secretary, Senior VP at Advaxis
Dr. McKearn joined Onconova in September, 2012. Dr. McKearn has over 30 years of experience in the translation of biotechnology and science into innovative products that address unmet medical needs in oncology.
For the past 10 years, he served as Vice President, Medical Affairs and then as Vice President, Strategic Clinical Affairs at Agennix, Inc. (formerly GPC Biotech) where he was responsible for clinical and regulatory development strategies for new drug candidates through to eventual product registration. Prior to joining GPC Biotech in 2002, he held several executive positions both in biotech and pharmaceutical organizations, including Executive Director of Strategic Science & Medicine at Bristol-Myers Squibb.
Dr. McKearn was a founder of Cytogen Corporation in 1981 and later served as its Chief Executive Officer. He has served on numerous executive boards and is currently a Director of Advaxis, Inc. and Anima Cell Metrology Ltd.